Journal & Article

Biochemistry & Biology

I/F
# Journal I/F

NATURE REVIEWS DRUG DISCOVERY

Top companies and drugs by sales in 2024 Outlook for medicines development and use in 2025. 2024 FDA approvals. FDA approves next-generation triple therapy for cystic fibrosis. DLL3 draws two antibody-drug conjugate deals. 2024 FDA approvals exceed average number but have lower sales projections. Biopharma dealmaking in 2024. Engineered T cells traverse new terrain. Pairing up with GLP-1 to combat obesity. Lipid nanoparticle ferries therapeutic mRNA to the placenta. Cough suppressant reverses lung scarring. Harnessing the biology of regulatory T cells to treat disease. Targeting lysine acetylation readers and writers. Vaccines for cancer prevention: exploring opportunities and navigating challenges. Antiviral target compound profile for pandemic preparedness. The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships. Na V 1.8 inhibitor poised to provide opioid-free pain relief. FDA approves L-amino acid decarboxylase deficiency gene therapy. FDA approves first menin inhibitor, for acute leukaemia. Top product forecasts for 2025. Upcoming FDA approval decisions in Q1 2025. Can non-canonical amino acids open up non-canonical drug discovery opportunities? Two decades of new drug approvals in Japan. StitchR platform joins up gene therapy payloads. NK2R agonist delivers one-two punch to obesity. Covalent inhibitor engages oncogenic AKT kinase. ENGases to treat IgG-mediated diseases. DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications. The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap. Senescence as a therapeutic target in cancer and age-related diseases. Author Correction: B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Clinical development success rates for durable cell and gene therapies. Genetics opens new route to degrader discovery. A platform for personalized ASO therapeutics. Adrenomedullin triggers insulin resistance. Reversing lysosomal dysfunction to treat PAH. Oral STING agonist inhibits tumour growth. Androgen membrane receptor modulates muscle strength. MYC in cancer: from undruggable target to clinical trials. Can large, simple trials bring drug developers back to common diseases? First muscle-growing antibody heads to the FDA, with obesity opportunities on the horizon. Approvals by the China NMPA in 2024. A new European platform for advancing regulatory science research. FDA approves TROP2-targeted antibody-drug conjugate for breast cancer. Directing autophagy to degrade cell surface receptors. Designer proteins take the bite out of snake venom. Peptide blocks phase separation and oncogenic transcription. Voltage-gated sodium channels in excitable cells as drug targets. PKC modulator promotes remyelination. New target to tackle coronaviruses.